Kura Oncology, Inc.
NASDAQ:KURABiotechnology
+$0.07 today
- Market cap
- $674.39M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
Volume 2.46M
Average 1.66M
KURA Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Kura Oncology, Inc.NASDAQ: KURA
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $5.49M fell 26.8% year over year, behind the -2.3% change in trailing-twelve-month other income / expenses. Sequentially, it rose 2.8% from the prior quarter. Over 3 fiscal years it compounded at +84.5% a year.
Context
- Other income / expenses amounted to 37.4% of revenue in FY2025, down 2.0 pp from a year earlier.
- Other income / expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -26.8% toward the trailing-twelve-month pace of -2.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 25.26M USD
- Year-over-year change
- +19.0%
- 4-year CAGR
- +137.6%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.26M | +19.0% |
| FY2024 | 2024-12-31 | 21.23M | +61.2% |
| FY2023 | 2023-12-31 | 13.17M | +227.3% |
| FY2022 | 2022-12-31 | 4.03M | +408.2% |
| FY2021 | 2021-12-31 | 792K | — |
Other Income / Expenses vs competitors
How KURA compares with its peers on the latest reported figures
- KURA's LTM Mar 2026 other income / expenses of $23.26M is the 2nd highest of the 11 companies compared; the peer median is $7.74M.
- Its year-over-year change of -2.3% is the 6th highest of 11, against a peer median of -5.6%.
- Other income / expenses amounts to 32.5% of revenue for KURA, versus a peer median of 27.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2025 | $554.73M | +566.3% | +123.8% | 92.1% | |
| LTM Mar 2026 | $23.26M | -2.3% | +84.5% | 32.5% | |
| LTM Aug 2026 | $18.56M | -20.1% | +84.3% | 2.6% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $14.77M | +85.5% | — | — |
| LTM Mar 2026 | $14.69M | +6.7% | +72.3% | — | |
| LTM Mar 2026 | $11.81M | -31.7% | +52.7% | — | |
| LTM Sep 2026 | $3.68M | +270.3% | +29.5% | — | |
| LTM Mar 2026 | $2.67M | -17.9% | +37.4% | 507.8% | |
| LTM Mar 2026 | -$2.61M | +55.1% | — | 0.9% | |
| LTM Mar 2026 | -$19.72M | -255.1% | — | 9.1% | |
| LTM Mar 2026 | -$23.11M | -31.1% | — | 46.6% | |
| Peer median (excluding KURA) | $7.74M | -5.6% | +62.5% | 27.8% | |
Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 53.88M | 67.48M |
| Cost of Revenue | 0 | 0 | 849K | 0 | 57K |
| Gross Profit | 0 | 0 | (849K) | 53.88M | 67.43M |
| Gross Margin | — | — | — | 100.0% | 99.9% |
| Research & Development | 84.72M | 92.81M | 115.24M | 169.97M | 251.07M |
| Selling, General & Admin | 46.54M | 47.05M | 50.57M | 77.11M | 119.98M |
| Operating Expenses | 131.26M | 139.87M | 164.96M | 247.08M | 371.06M |
| Depreciation & Amortization | 558K | 759K | 849K | 848K | 1.03M |
| EBITDA | (129.49M) | (134.85M) | (150.23M) | (169.5M) | (275.83M) |
| EBITDA Margin | — | — | — | -314.6% | -408.7% |
| Operating Income | (131.26M) | (139.87M) | (165.8M) | (193.2M) | (303.63M) |
| Operating Margin | — | — | — | -358.5% | -449.9% |
| Interest Income | 1.21M | 4.25M | 14.72M | 22.85M | 26.77M |
| Interest Expense | 414K | 229K | 1.55M | 1.62M | 1.51M |
| Other Income / Expenses | 792K | 4.03M | 13.17M | 21.23M | 25.26M |
| Income Before Tax | (130.47M) | (135.84M) | (152.63M) | (171.97M) | (278.37M) |
| Pre-Tax Margin | — | — | — | -319.1% | -412.5% |
| Income Tax Expense | 0 | 0 | 0 | 2.02M | 297K |
| Net Income | (130.47M) | (135.84M) | (152.63M) | (173.98M) | (278.67M) |
| Net Margin | — | — | — | -322.9% | -412.9% |
| EPS (Basic) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) |
| EPS (Diluted) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) |
| Weighted Avg Shares | 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
| Weighted Avg Shares (Diluted) | 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
Kura Oncology, Inc.
NASDAQ:KURA
Intrinsic Alpha fair value
Locked
Current Price
$7.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.